Sarepta Therapeutics Inc. (SRPT) Given “Underperform” Rating at Jefferies Group
Several other brokerages have also weighed in on SRPT. Royal Bank Of Canada reaffirmed a hold rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Vetr raised shares of Sarepta Therapeutics from a strong sell rating to a buy rating and set a $17.28 target price for the company in a research note on Thursday, June 2nd. William Blair reissued a market perform rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. Needham & Company LLC raised their price objective on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a buy rating in a research note on Friday, July 22nd. Finally, Robert W. Baird reissued an outperform rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Thursday. The firm’s market cap is $2.67 billion. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $56.80. The firm’s 50-day moving average is $28.17 and its 200-day moving average is $21.37.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the firm earned ($0.87) EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post ($4.98) earnings per share for the current year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.90% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of SRPT. Teacher Retirement System of Texas raised its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $211,000. National Planning Corp raised its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the last quarter. Finally, First Allied Advisory Services Inc. raised its stake in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the last quarter. Institutional investors own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.